USA flag logo/image

An Official Website of the United States Government

Novel Therapeutic Approach to Acute Lung Injury

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89300
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
HL091601
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NAVIGEN, INC.
383 Colorow Drive SALT LAKE CITY, UT 84108
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Novel Therapeutic Approach to Acute Lung Injury
Agency: HHS
Contract: 1R43HL091601-01
Award Amount: $147,660.00
 

Abstract:

DESCRIPTION (provided by applicant): Navigen Pharmaceutical will develop a novel class of protein therapies for treating acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). This work is based on the discovery by our scientific founder, Dean Li, M.D., Ph.D., that there are endogenous signaling pathways that enhance vascular stability and inhibit multiple cytokines and growth factors from inciting vascular leak and edema. Specifically, Dr. Li has found an endothelial specific receptor, Robo4, that is expressed in mature vessels and is upregulated following endothelial injury. Robo4 activated by its cognate ligand, recombinant Slit proteins, reduces agonist induced vascular leak in vitro and in vivo. The central goal of this application is to de velop a new class of biologic agents that reduces the noncardiac pulmonary edema of ALI/ARDs. Specific Aim 1: Generate a superior Robo4 agonist by defining the minimum active domain of its endogenous ligand, Slit-2, and creating a Fc fusion protein Specific Aim 2: Investigate whether candidate recombinant Robo4 agonists generated in Aim 1 inhibit vascular leak and reduce acute lung injury in vivo. We will use this Phase I SBIR to generate and compare Robo4 agonists for ease of purifi cation, stability and efficacy. These experiments will lead to a candidate Robo4 agonist that Navigen will advance toward clinical development during a subsequent Phase II for this SBIR. PUBLIC HEALTH RELEVANCE: Navigen Pharmaceutical will develop a novel class of protein therapies for treating acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Both ALI/ARDS are deadly diseases, with no specific treatment and is the cause of death in chemical and biologic warfare and flu pandemics. We will use this Phase I SBIR to generate a candidate biologic that Navigen will advance toward clinical development during a subsequent Phase II for this SBIR.

Principal Investigator:

Business Contact:

Small Business Information at Submission:

NAVIGEN, INC.
NAVIGEN, INC. 1327 MICHIGAN AVE SALT LAKE CITY, UT 84105

EIN/Tax ID: 120853586
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No